AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson’s disease. The placebo-controlled study enrolled 34 participants, with 25 receiving ACI-7104.056 and nine receiving placebo. The trial included an 18-month treatment period followed by a six-month safety follow-up. […]